PG Electroplast Limited (PGEL) has announced its financial results for the second quarter of the fiscal year 2027, showcasing robust growth across all key financial metrics. The company reported a 42.5% increase in sales, reaching INR 933.88 crores, and a 54.8% surge in EBITDA, hitting INR 69.14 crores. This impressive performance highlights PGEL’s strong operational efficiency and market demand for its diversified product offerings.

Financial Highlights

The company’s consolidated revenue for the first half of FY2027 crossed INR 2,950 crores, marking a historic milestone. Notably, the AC business grew by 36.2% year-on-year to INR 1,561.1 crores, while the Washing Machines business saw a remarkable 60.7% growth to INR 504.8 crores. The Electronics business also contributed significantly with a 90.3% year-on-year growth, accounting for 12.1% of total revenues.

Operational Efficiency

PGEL’s operational efficiency is further demonstrated by its improved EBITDA margin, which rose to 7.4% in Q2 FY2027 from 6.8% in the same period last year. The company’s net income also surged by 395.2% to INR 13.67 crores, underscoring its effective cost management and strategic growth initiatives.

Future Outlook

Looking ahead, PG Electroplast Limited remains optimistic about its growth trajectory. The company’s expansion projects are on track, and the commencement of commercial production from two new facilities is anticipated soon. This strategic expansion, coupled with continuous innovation and market demand, positions PGEL for sustained growth in the coming quarters.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of PG Electroplast Limited

PG Electroplast Limited belongs to the Technology › Electronic Components sector. Here’s a quick read on where the business and the stock stand today.

PG falls 15.6% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 33.8% and profits at 36.4% CAGR. Both numbers are exceptional. The stock holds at 41% of its 52-week range with RSI at 47. In other words, neither side has a clear edge right now. Revenue grows at 33.8% and profits at 36.4% CAGR, with D/E of 0.00. Meanwhile, the stock dips 15.6% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of PG Electroplast Limited.

Avalon Technologies Limited (NSE: AVALON) has issued a clarification regarding recent media reports about a proposed stake sale by Mr. Bhaskar Srinivasan’s promoter group. The company emphasized that the reference to the KBS Family Trust should not be construed as a reference to Mr. Kunhamed Bicha or his promoter group, who are not involved in this proposed sale. For transparency, as of September 29, 2026, the shareholding of Mr. Bhaskar Srinivasan’s promoter group in Avalon is detailed below:

Shareholding Details

The shareholding distribution is as follows:

Bhaskar Srinivasan: 62,70,355 shares (9.38%)

BBS Family Trust: 20,20,710 shares (3.02%)

KBS Family Trust: 20,20,710 shares (3.02%)

Dolphin Family Trust: 1,000 shares (0.00%)

Together, these holdings make up a total of 1,03,12,775 shares (15.42%) of Avalon Technologies Limited. Avalon Technologies Limited remains committed to maintaining transparency and providing accurate information to its shareholders and stakeholders. For the latest regulatory disclosures on promoter shareholding, investors and stakeholders are advised to refer to the company’s official announcements.

For more details on Avalon Technologies Limited, please visit our website or contact our Chief Financial Officer, Suresh Veerappan.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Avalon Technologies Limited

Avalon Technologies Limited belongs to the Technology › Electronic Components sector. Here’s a quick read on where the business and the stock stand today.

Avalon gains 28.2% over three months and trades near its 52-week highs. The PEG reaches 3.98. The stock trades on brand and index weight, not on growth. Thin margins at 7.6% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Buyers show up with 2.0x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The business grows revenue at 19.3% and profits at 29.1%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 3.98 premium is usually justified. Check Fundamentals of Avalon Technologies Limited.

Syrma SGS Technology Limited (NSE: SYRMA) inaugurated its new Medical Plastics and Precision Molding Facility in Jodhpur, Rajasthan, marking a significant milestone in the company’s expansion of its MedTech manufacturing capabilities. With a plant area of over 120,000 sq. ft., the facility brings together capabilities in medical plastics and precision molding, including injection molding, extrusion, blow molding, and tooling.

Enhanced Manufacturing Capabilities

The new facility is designed to support the manufacture of precision medical components, including multi-cavity and tight-tolerance molded components, medical and diagnostic tubing, customized tubing profiles, and other specialized applications. This expansion strengthens the broader manufacturing ecosystem of the Syrma SGS Group, with 17 global production sites and four design and innovation centers.

Strategic Investment

Commenting on the inauguration, Sandeep Tandon, Executive Chairman of Syrma SGS Technology Limited, said: “The inauguration of the Jodhpur facility marks an important milestone in the evolution of our MedTech capabilities and reflects our long-term commitment to building specialized, high-value manufacturing capabilities in India in this industry. As the global MedTech industry continues to evolve, we see significant opportunity to contribute through investments in precision manufacturing, technology, and scale.”

As a result, Syrma Johari MedTech’s position as a design-led global MedTech CDMO is further strengthened, with capabilities spanning design and engineering, precision plastics, tooling, cleanroom operations, and assembly. The company supports MedTech programs across areas including diagnostics, medical aesthetics, patient monitoring, surgical and interventional care, critical care, rehabilitation, and physical therapy.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Syrma SGS Technology Limited

Syrma SGS Technology Limited belongs to the Technology › Electronic Components sector. Here’s a quick read on where the business and the stock stand today.

Syrma gains 24.8% over three months and trades near its 52-week highs. Thin margins at 6.7% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue grows at 32.8% and profits at 38.6% CAGR. Both numbers are exceptional. The stock trades at 96% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 32.8% and profits at 38.6%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.29 premium is usually justified. Check Fundamentals of Syrma SGS Technology Limited.